Allurion Technologies (ALUR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $11.8M, up 25% sequentially but down 9% year-over-year, with record procedure volumes and over 10,000 balloon placements for a second consecutive quarter.

• Loss from operations decreased 30% year-over-year to $9.3M, and net loss improved to $2.2M from $22.7M in Q2 2023.

• Over $22M was raised in July 2024 through public and private offerings, strengthening the cash position to about $37M post-financing.

• French regulatory authority suspended Allurion Balloon sales in August 2024, impacting a key market; remediation plan is underway.

• The company received a NYSE notice in August 2024 for non-compliance with the $1.00 minimum share price requirement.

Financial highlights

• Q2 2024 revenue was $11.8M, up $2.3M (25%) sequentially but down $1.2M (9%) year-over-year; six-month revenue was $21.2M, down 22%.

• Gross margin was 76% in Q2 2024, compared to 77% a year ago.

• Sales and marketing expenses dropped to $6.7M, R&D to $4.3M, and G&A rose to $7.3M due to $1.9M in financing costs.

• Loss from operations was $9.3M, a 30% improvement year-over-year; net loss was $2.2M.

• Cash and equivalents were $19.3M at quarter-end, increasing to about $37M after July financing.

Outlook and guidance

• 2024 revenue guidance updated to $40M–$45M, with procedure volume growth of 10–15%.

• Profitability targeted by end of 2025, driven by cost reductions and operational efficiency.

• Management expects continued operating losses and negative cash flows in the near term, with substantial doubt about going concern without additional capital.

• France market disruption and macro headwinds in Latin America and Asia Pacific expected to slow growth and inventory restocking in H2 2024.

• Focus on resuming sales in France, obtaining regulatory approvals, and expanding in new markets.